Interleukin-6, -7, -8 and -10 predict outcome in acute myocardial infarction complicated by cardiogenic shock

Prondzinsky, Roland; Unverzagt, Susanne; Lemm, Henning; Wegener, Nikolas-Arne; Schlitt, Axel; Heinroth, Konstantin M; Dietz, Sebastian; Buerke, Ute; Kellner, Patrick; Loppnow, Harald; Fiedler, Martin G; Thiery, Joachim; Werdan, Karl; Buerke, Michael (2012). Interleukin-6, -7, -8 and -10 predict outcome in acute myocardial infarction complicated by cardiogenic shock. Clinical research in cardiology, 101(5), pp. 375-84. Heidelberg: Springer-Medizin-Verlag 10.1007/s00392-011-0403-3

Preview

Text Prondzinsky2012_Article_Interleukin-6-7-8And-10Predict.pdf - Published Version Available under License Publisher holds Copyright. Download (250kB) | Preview

The IABP-SHOCK-trial was a morbidity-based randomized controlled trial in patients with infarction-related cardiogenic shock (CS), which used the change of the quantified degree of multiorgan failure as determined by APACHE II score over a 4-day period as primary outcome measure. The prospective hypothesis was that adding IABP therapy to "standard care" would improve CS-triggered multi organ dysfunction syndrome (MODS). The primary endpoint showed no difference between conventionally managed cardiogenic shock patients and those with IABP support. In an inflammatory marker substudy, we analysed the prognostic value of interleukin (IL)-1β, -6, -7, -8, and -10 in patients with acute myocardial infarction complicated by cardiogenic shock.

Interest & Impact

Downloads

198 since deposited on 04 Oct 2013
86 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item